Dexamethasone suppresses tumor-specific T cell proliferation and differentiation but not activity in antigen-experienced mice.
Fuente:
Zenodo
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Format: | Recurso digital |
| Veröffentlicht: |
Zenodo
2025
|
| Online-Zugang: | |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| _version_ | 1866901375844089856 |
|---|---|
| author | Nagaoka, Koji |
| author_facet | Nagaoka, Koji |
| contents | <p><span lang="EN-US">Healthy mice were administered activated pmel-1 T cells labeled with the congenic marker Thy1.1 on day -21 and vaccinated for the first time with a gp100 vaccine on day -19. From day -2 until day 6, the mice were administered 3 mg/kg dexamethasone daily. On day 0, they were administered the vaccine a second time.<span> </span>Spleens were harvested for flow cytometry on day 7.</span></p> <p> </p> <p><span lang="EN-US">The cells were stimulated with 1 µg/ml hgp100 peptide in the presence of 10 µg/ml brefeldin A at 37°C for 4 h. The cells were stained with Zombie Yellow, FITC-conjugated anti-Thy1.1, APC/Cyanine7-conjugated anti-CD8, Pacific Blue-conjugated anti-CD3, PE/Dazzle594-conjugated anti-B220, anti-F4/80, anti-NK1.1 and anti-Ly6G, followed by fixation, permeabilization and staining with PE/Cyanine7-conjugated anti-IFNγ, PE-conjugated anti-TNF</span><span lang="EN-US">α</span><span lang="EN-US"> and APC-conjugated anti-Granzyme B (BioLegend) using Intracellular Staining Fixation Buffer and Intracellular Staining Permeabilization Wash Buffer (10X) (BioLegend) according to the manufacturer's protocols.</span></p> |
| format | Recurso digital |
| id | zenodo_https___doi_org_10_5281_zenodo_17197426 |
| institution | Zenodo |
| language | |
| publishDate | 2025 |
| publisher | Zenodo |
| record_format | zenodo |
| spellingShingle | Dexamethasone suppresses tumor-specific T cell proliferation and differentiation but not activity in antigen-experienced mice. Nagaoka, Koji <p><span lang="EN-US">Healthy mice were administered activated pmel-1 T cells labeled with the congenic marker Thy1.1 on day -21 and vaccinated for the first time with a gp100 vaccine on day -19. From day -2 until day 6, the mice were administered 3 mg/kg dexamethasone daily. On day 0, they were administered the vaccine a second time.<span> </span>Spleens were harvested for flow cytometry on day 7.</span></p> <p> </p> <p><span lang="EN-US">The cells were stimulated with 1 µg/ml hgp100 peptide in the presence of 10 µg/ml brefeldin A at 37°C for 4 h. The cells were stained with Zombie Yellow, FITC-conjugated anti-Thy1.1, APC/Cyanine7-conjugated anti-CD8, Pacific Blue-conjugated anti-CD3, PE/Dazzle594-conjugated anti-B220, anti-F4/80, anti-NK1.1 and anti-Ly6G, followed by fixation, permeabilization and staining with PE/Cyanine7-conjugated anti-IFNγ, PE-conjugated anti-TNF</span><span lang="EN-US">α</span><span lang="EN-US"> and APC-conjugated anti-Granzyme B (BioLegend) using Intracellular Staining Fixation Buffer and Intracellular Staining Permeabilization Wash Buffer (10X) (BioLegend) according to the manufacturer's protocols.</span></p> |
| title | Dexamethasone suppresses tumor-specific T cell proliferation and differentiation but not activity in antigen-experienced mice. |
| url | https://doi.org/10.5281/zenodo.17197426 |